Truist Financial Lowers Integra LifeSciences (NASDAQ:IART) Price Target to $12.00

Integra LifeSciences (NASDAQ:IART) had its price target decreased by analysts at Truist Financial from $13.00 to $12.00 in a research note issued on Wednesday, MarketBeat Ratings reports. The firm currently has a “hold” rating on the life sciences company’s stock. Truist Financial’s price target would indicate a potential upside of 10.70% from the company’s current price.

A number of other equities analysts also recently issued reports on IART. Citigroup dropped their price target on Integra LifeSciences from $11.00 to $9.00 and set a “sell” rating on the stock in a research note on Wednesday, March 11th. Wall Street Zen downgraded Integra LifeSciences from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Argus restated a “hold” rating on shares of Integra LifeSciences in a research note on Wednesday. Wells Fargo & Company upgraded Integra LifeSciences to a “hold” rating in a research note on Wednesday, March 18th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Integra LifeSciences in a research note on Friday, March 27th. One research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat, Integra LifeSciences has a consensus rating of “Reduce” and a consensus target price of $14.20.

Integra LifeSciences Stock Down 1.7%

Integra LifeSciences stock opened at $10.84 on Wednesday. The firm has a market cap of $844.87 million, a price-to-earnings ratio of -1.61 and a beta of 1.06. The stock has a fifty day simple moving average of $10.23 and a two-hundred day simple moving average of $12.02. Integra LifeSciences has a 12 month low of $8.70 and a 12 month high of $17.54. The company has a current ratio of 2.54, a quick ratio of 1.46 and a debt-to-equity ratio of 1.66.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Thursday, February 26th. The life sciences company reported $0.83 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.04. The business had revenue of $434.93 million during the quarter, compared to analyst estimates of $429.62 million. Integra LifeSciences had a positive return on equity of 14.76% and a negative net margin of 31.58%.The company’s quarterly revenue was down 1.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.97 EPS. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. Equities analysts predict that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Hedge Funds Weigh In On Integra LifeSciences

Several institutional investors and hedge funds have recently bought and sold shares of IART. Rubric Capital Management LP lifted its position in Integra LifeSciences by 58.4% during the second quarter. Rubric Capital Management LP now owns 7,353,934 shares of the life sciences company’s stock valued at $90,233,000 after purchasing an additional 2,710,262 shares in the last quarter. Paradigm Capital Management Inc. NY lifted its position in Integra LifeSciences by 57.5% during the second quarter. Paradigm Capital Management Inc. NY now owns 2,181,500 shares of the life sciences company’s stock valued at $26,767,000 after purchasing an additional 796,300 shares in the last quarter. Invenomic Capital Management LP lifted its position in Integra LifeSciences by 78.3% during the fourth quarter. Invenomic Capital Management LP now owns 1,055,941 shares of the life sciences company’s stock valued at $13,115,000 after purchasing an additional 463,729 shares in the last quarter. Kotler Kevin purchased a new position in Integra LifeSciences during the fourth quarter valued at $5,309,000. Finally, SG Americas Securities LLC purchased a new position in Integra LifeSciences during the fourth quarter valued at $4,722,000. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.